Dynavax Technologies Corporation

Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company with multiple product candidates in development for the prevention of infectious disease, the treatment of autoimmune and inflammatory diseases, and the treatment of cancer. The Company develops immunotherapies based on cutting-edge Toll-Like Receptor biology and its ability to modulate the immune system.

Dynavax Technologies Corporation's clinical-stage product candidates include HBsAg-1018 is an adult hepatitis B vaccine in Phase 3 development that utilizes a proprietary TLR9 agonist to elicit a focused immune response designed to provide protection against hepatitis B; and the Company's lead cancer immunotherapy compound, SD-101, is a TLR9 agonist designed specifically for cancer and capable of maximal type 1 IFN induction and efficient maturation of plasmacytoid dendritic cells to antigen-presenting cells. 

Berkeley, US
Size (employees)
251 (est)+8%
Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, US

Dynavax Technologies Corporation Office Locations

Dynavax Technologies Corporation has an office in Berkeley
Berkeley, US (HQ)
100 2929 Seventh Street

Dynavax Technologies Corporation Data and Metrics

Dynavax Technologies Corporation Financial Metrics

Dynavax Technologies Corporation's revenue was reported to be $11 m in FY, 2016 which is a 173% increase from the previous period.

Revenue (FY, 2016)

11 m

Revenue growth (FY, 2015 - FY, 2016), %


Net income (FY, 2016)

(112.4 m)

EBIT (FY, 2016)

(110.7 m)

Market capitalization (06-Jul-2017)

468.4 m

Closing share price (06-Jul-2017)


Cash (31-Dec-2016)

24.3 m
Dynavax Technologies Corporation's current market capitalization is $468.4 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016


11.3 m11 m4.1 m11 m

Revenue growth, %


R&D expense

50.9 m84.6 m86.9 m84.5 m

General and administrative expense

25.9 m17.4 m22.2 m37.3 m

Operating expense total

77.7 m102.3 m109.1 m121.8 m


(66.5 m)(91.3 m)(105.1 m)(110.7 m)

EBIT margin, %


Interest expense

(35 k)(572 k)(572 k)

Interest income

116 k191 k205 k755 k

Net Income

(66.7 m)(90.7 m)(106.8 m)(112.4 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016


23.1 m49.5 m44.8 m24.3 m

Accounts Receivable

1.6 m727 k1.4 m


1.4 m4.1 m2.4 m6.8 m

Current Assets

192.4 m127.4 m199.9 m89.6 m


8.7 m7.9 m13.8 m17.2 m


2.6 m2.3 m2 m2 m

Total Assets

204.6 m138.3 m216.6 m109.7 m

Accounts Payable

1.9 m1.2 m3.4 m3.8 m

Total Debt

9.6 m

Current Liabilities

16.2 m20.3 m28.8 m20 m

Non-Current Liabilities

2.1 m17.5 m769 k443 k

Total Liabilities

18.3 m37.8 m29.6 m20.5 m

Additional Paid-in Capital

688.4 m695.1 m889.7 m905 m

Retained Earnings

(502.2 m)(592.9 m)(699.7 m)(812.2 m)

Total Equity

186.3 m100.5 m187.1 m89.2 m

Debt to Equity Ratio

0.1 x

Debt to Assets Ratio

0.1 x

Financial Leverage

1.1 x1.4 x1.2 x1.2 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(66.7 m)(90.7 m)(106.8 m)(112.4 m)

Depreciation and Amortization

1.3 m1.4 m1.4 m2.3 m

Accounts Receivable

(622 k)900 k(667 k)52 k


677 k(2.7 m)1.6 m560 k

Accounts Payable

(657 k)(523 k)1.2 m1.2 m

Cash From Operating Activities

(58.7 m)(73.7 m)(92.6 m)(107.1 m)

Cash From Investing Activities

(51.4 m)90.6 m(85.8 m)86.2 m

Cash From Financing Activities

125.4 m9.9 m174 m531 k

Interest Paid

720 k720 k
USDY, 2016


47.2 k

Financial Leverage

1.2 x

Dynavax Technologies Corporation Operating Metrics

FY, 2016

Phase III Trials


Phase II Trials


Phase I Trials


Phase Preclinical


Patents (US)


Patents (foreign)


Patents Pending


Dynavax Technologies Corporation Market Value History

Dynavax Technologies Corporation Revenue Breakdown

Dynavax Technologies Corporation Company Life and Culture

You may also be interested in